Opus Genetics Aligns with FDA on Phase 3 Trial Design
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: NASDAQ.COM
- Trial Design Confirmation: Opus Genetics achieved alignment with the FDA during a Type B meeting, confirming the design of its Phase 3 clinical trial for LCA5-associated inherited retinal disease, marking a significant advancement in the rare disease sector.
- Biologics License Application: The FDA indicated that Opus Genetics may submit a Biologics License Application based on efficacy at the six-month primary endpoint, with 12-month durability data to be submitted during the review process, signaling positive market potential for the product.
- Participant Recruitment Progress: The Phase 3 study plans to enroll eight participants, with seven already enrolled and completing the run-in period, and dosing expected to begin in Q4 2026, demonstrating rapid clinical advancement by the company.
- Positive Stock Reaction: In pre-market trading on NasdaqCM, Opus Genetics shares rose 2.55% to $4.3378, reflecting market optimism regarding the company's clinical progress.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IRD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IRD
Wall Street analysts forecast IRD stock price to rise
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.070
Low
6.00
Averages
8.00
High
9.00
Current: 4.070
Low
6.00
Averages
8.00
High
9.00
About IRD
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Opus Genetics Aligns with FDA on Phase 3 Study for LCA5 Treatment
- FDA Meeting Outcome: Opus Genetics confirmed the design of its Phase 3 clinical trial for LCA5-associated IRDs during a Type B RDEP meeting with the FDA, with dosing expected to begin in Q4 2026, marking a significant advancement in treating childhood blindness.
- Trial Design Details: The study plans to enroll eight participants, utilizing microperimetry to assess treatment effects, with preliminary results from Phase 1/2 showing an average retinal sensitivity improvement of approximately 10.5 decibels, indicating potential efficacy of the treatment.
- BLA Submission Prospects: The FDA indicated that Opus Genetics may submit a Biologics License Application (BLA) based on six-month efficacy data, paving the way for future market access and holding significant strategic importance for the company.
- Therapeutic Potential: LCA5-associated inherited retinal disease represents a severe form of childhood blindness, and the FDA's ongoing support and engagement provide strong momentum for Opus Genetics' treatment program, expected to bring hope to patients and families.
See More
Opus Genetics Aligns with FDA on Phase 3 Trial Design
- Trial Design Confirmation: Opus Genetics achieved alignment with the FDA during a Type B meeting, confirming the design of its Phase 3 clinical trial for LCA5-associated inherited retinal disease, marking a significant advancement in the rare disease sector.
- Biologics License Application: The FDA indicated that Opus Genetics may submit a Biologics License Application based on efficacy at the six-month primary endpoint, with 12-month durability data to be submitted during the review process, signaling positive market potential for the product.
- Participant Recruitment Progress: The Phase 3 study plans to enroll eight participants, with seven already enrolled and completing the run-in period, and dosing expected to begin in Q4 2026, demonstrating rapid clinical advancement by the company.
- Positive Stock Reaction: In pre-market trading on NasdaqCM, Opus Genetics shares rose 2.55% to $4.3378, reflecting market optimism regarding the company's clinical progress.
See More
Opus Genetics Added to Russell Indexes, Enhancing Market Visibility
- Inclusion in Russell Indexes: Opus Genetics will be added to the Russell 3000, 2000, and Microcap indexes effective June 29, 2026, marking a significant recognition of the company's progress in gene therapy, which is expected to enhance investor attention.
- Market Capitalization Ranking: The Russell indexes include the top 4,000 U.S. stocks based on market capitalization as of April 30, 2026, and Opus's inclusion ensures automatic membership in both large-cap and small-cap indexes, further solidifying its market position.
- Boost in Investor Confidence: CEO George Magrath stated that being part of the Russell indexes will provide greater visibility to investors, potentially facilitating future financing and partnership opportunities, thereby accelerating the clinical development of its gene therapy products.
- Expanded Industry Influence: With approximately $12.2 trillion in assets benchmarked against the Russell indexes as of June 2025, Opus's inclusion will significantly enhance its influence in the biopharmaceutical sector, attracting more institutional investors to its innovative treatment solutions.
See More
Opus Genetics Updates on Gene Therapy Developments
- Gene Therapy Progress: Opus Genetics provided updates on various gene therapies for inherited retinal diseases at the R&D Science Forum, with OPGx-RDH12 set to begin clinical testing in Q4 this year, targeting approximately 30,900 patients with LCA, indicating significant therapeutic potential.
- Clinical Trial Plans: OPGx-MERTX, aimed at MERTK mutations causing severe vision loss, is expected to enter clinical testing in 2027, focusing on restoring retinal pigment epithelium metabolism, which suggests future treatment possibilities.
- Vision Improvement Results: In the Phase 1/2 trial of OPGx-LCA5, significant vision improvements were observed in both adult and pediatric patients after 24 and 6 months respectively, demonstrating the therapy's effectiveness and durability.
- Upcoming Trials: The company has initiated recruitment for the Phase 3 trial of OPGx-LCA5, with dosing expected to start in Q4 this year, while topline data from the Phase 1/2 trial for OPGx-BEST1 is anticipated in September 2026, further advancing the R&D pipeline.
See More
Wall Street's Latest Ratings and Price Target Adjustments
- Broadcom Rating Adjustment: Morgan Stanley raised Broadcom's price target from $485 to $502, reflecting strong performance amid high expectations, indicating a sustained growth trend that may attract more investor interest.
- RTX Upgraded to Buy: Jefferies upgraded RTX from hold to buy, emphasizing its leading position in aerospace and defense, with significant growth potential from market expansion and budget support, enhancing investor confidence.
- FedEx Freight Coverage Initiated: Wolfe initiated coverage on FedEx Freight with an Outperform rating, expecting material EPS growth in the coming years driven by company-specific pricing and margin opportunities, indicating a positive market outlook.
- Alphabet Maintained Buy Rating: Bank of America reiterated its buy rating on Alphabet, anticipating 2027 capex of $241 billion and $16 billion in free cash flow, showcasing strong performance in future market demand.
See More
Opus Genetics Reports Q1 Losses and Revenue Decline
- Earnings Miss: Opus Genetics reported a Q1 GAAP EPS of -$0.75, missing expectations by $0.60, indicating significant challenges in profitability that could undermine investor confidence.
- Revenue Decline: The company’s Q1 revenue of $2.16M represents a 50.6% year-over-year decline, falling short of expectations by $0.77M, reflecting weak market demand and poor product sales, which may lead to tighter cash flow in the future.
- Financing Support: Opus Genetics secured up to $155M in financing from Oberland Capital, providing essential operational funds that will help the company maintain R&D and market expansion efforts amid adversity.
- Historical Performance Review: Despite the poor Q1 results, historical earnings data suggests that the company has asymmetric upside potential with its LCA5 and BEST1 projects, indicating possible future business recovery.
See More
Opus Genetics Aligns with FDA on Phase 3 Study for LCA5 Treatment
- FDA Meeting Outcome: Opus Genetics confirmed the design of its Phase 3 clinical trial for LCA5-associated IRDs during a Type B RDEP meeting with the FDA, with dosing expected to begin in Q4 2026, marking a significant advancement in treating childhood blindness.
- Trial Design Details: The study plans to enroll eight participants, utilizing microperimetry to assess treatment effects, with preliminary results from Phase 1/2 showing an average retinal sensitivity improvement of approximately 10.5 decibels, indicating potential efficacy of the treatment.
- BLA Submission Prospects: The FDA indicated that Opus Genetics may submit a Biologics License Application (BLA) based on six-month efficacy data, paving the way for future market access and holding significant strategic importance for the company.
- Therapeutic Potential: LCA5-associated inherited retinal disease represents a severe form of childhood blindness, and the FDA's ongoing support and engagement provide strong momentum for Opus Genetics' treatment program, expected to bring hope to patients and families.
See More
Opus Genetics Aligns with FDA on Phase 3 Trial Design
- Trial Design Confirmation: Opus Genetics achieved alignment with the FDA during a Type B meeting, confirming the design of its Phase 3 clinical trial for LCA5-associated inherited retinal disease, marking a significant advancement in the rare disease sector.
- Biologics License Application: The FDA indicated that Opus Genetics may submit a Biologics License Application based on efficacy at the six-month primary endpoint, with 12-month durability data to be submitted during the review process, signaling positive market potential for the product.
- Participant Recruitment Progress: The Phase 3 study plans to enroll eight participants, with seven already enrolled and completing the run-in period, and dosing expected to begin in Q4 2026, demonstrating rapid clinical advancement by the company.
- Positive Stock Reaction: In pre-market trading on NasdaqCM, Opus Genetics shares rose 2.55% to $4.3378, reflecting market optimism regarding the company's clinical progress.
See More
Opus Genetics Added to Russell Indexes, Enhancing Market Visibility
- Inclusion in Russell Indexes: Opus Genetics will be added to the Russell 3000, 2000, and Microcap indexes effective June 29, 2026, marking a significant recognition of the company's progress in gene therapy, which is expected to enhance investor attention.
- Market Capitalization Ranking: The Russell indexes include the top 4,000 U.S. stocks based on market capitalization as of April 30, 2026, and Opus's inclusion ensures automatic membership in both large-cap and small-cap indexes, further solidifying its market position.
- Boost in Investor Confidence: CEO George Magrath stated that being part of the Russell indexes will provide greater visibility to investors, potentially facilitating future financing and partnership opportunities, thereby accelerating the clinical development of its gene therapy products.
- Expanded Industry Influence: With approximately $12.2 trillion in assets benchmarked against the Russell indexes as of June 2025, Opus's inclusion will significantly enhance its influence in the biopharmaceutical sector, attracting more institutional investors to its innovative treatment solutions.
See More
Opus Genetics Updates on Gene Therapy Developments
- Gene Therapy Progress: Opus Genetics provided updates on various gene therapies for inherited retinal diseases at the R&D Science Forum, with OPGx-RDH12 set to begin clinical testing in Q4 this year, targeting approximately 30,900 patients with LCA, indicating significant therapeutic potential.
- Clinical Trial Plans: OPGx-MERTX, aimed at MERTK mutations causing severe vision loss, is expected to enter clinical testing in 2027, focusing on restoring retinal pigment epithelium metabolism, which suggests future treatment possibilities.
- Vision Improvement Results: In the Phase 1/2 trial of OPGx-LCA5, significant vision improvements were observed in both adult and pediatric patients after 24 and 6 months respectively, demonstrating the therapy's effectiveness and durability.
- Upcoming Trials: The company has initiated recruitment for the Phase 3 trial of OPGx-LCA5, with dosing expected to start in Q4 this year, while topline data from the Phase 1/2 trial for OPGx-BEST1 is anticipated in September 2026, further advancing the R&D pipeline.
See More
Wall Street's Latest Ratings and Price Target Adjustments
- Broadcom Rating Adjustment: Morgan Stanley raised Broadcom's price target from $485 to $502, reflecting strong performance amid high expectations, indicating a sustained growth trend that may attract more investor interest.
- RTX Upgraded to Buy: Jefferies upgraded RTX from hold to buy, emphasizing its leading position in aerospace and defense, with significant growth potential from market expansion and budget support, enhancing investor confidence.
- FedEx Freight Coverage Initiated: Wolfe initiated coverage on FedEx Freight with an Outperform rating, expecting material EPS growth in the coming years driven by company-specific pricing and margin opportunities, indicating a positive market outlook.
- Alphabet Maintained Buy Rating: Bank of America reiterated its buy rating on Alphabet, anticipating 2027 capex of $241 billion and $16 billion in free cash flow, showcasing strong performance in future market demand.
See More
Opus Genetics Reports Q1 Losses and Revenue Decline
- Earnings Miss: Opus Genetics reported a Q1 GAAP EPS of -$0.75, missing expectations by $0.60, indicating significant challenges in profitability that could undermine investor confidence.
- Revenue Decline: The company’s Q1 revenue of $2.16M represents a 50.6% year-over-year decline, falling short of expectations by $0.77M, reflecting weak market demand and poor product sales, which may lead to tighter cash flow in the future.
- Financing Support: Opus Genetics secured up to $155M in financing from Oberland Capital, providing essential operational funds that will help the company maintain R&D and market expansion efforts amid adversity.
- Historical Performance Review: Despite the poor Q1 results, historical earnings data suggests that the company has asymmetric upside potential with its LCA5 and BEST1 projects, indicating possible future business recovery.
See More
